CALL/ROCHE GS/450/0.1/21.06.24 Stock

Warrant

DE000GZ6BTB5

Real-time BOERSE MUENCHEN 02:26:18 2024-05-17 pm EDT
0.001 EUR 0.00% Intraday chart for CALL/ROCHE GS/450/0.1/21.06.24
6 months-92.31%
Current year-88.89%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-17 0.001 0.00%
24-05-16 0.001 0.00%
24-05-15 0.001 0.00%
24-05-14 0.001 0.00%
24-05-13 0.001 0.00%

Real-time BOERSE MUENCHEN

Last update May 17, 2024 at 02:26 pm EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer Goldman Sachs
WKN GZ6BTB
ISINDE000GZ6BTB5
Date issued 2022-12-29
Strike 450 CHF
Maturity 2024-06-21 (33 Days)
Parity 10 : 1
Emission price 0.07
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.21
Lowest since issue 0.001
Spread 0.149
Spread %99.33%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
237.1 CHF
Average target price
279.4 CHF
Spread / Average Target
+17.84%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW